Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors

PURPOSE: IL2 immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical utility is limited due to pharmacokinetic challenges as well as vascular leak syndrome and other life-threatening toxicities experienced by patients. We developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Amanda M., Aghlara-Fotovat, Samira, Castillio, Bertha, Hernandez, Andrea, Pugazenthi, Aarthi, Lee, Hyun-Sung, Jang, Hee-Jin, Nguyen, Annie, Lu, Alexander, Burt, Bryan M., Ghanta, Ravi K., Veiseh, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713361/
https://www.ncbi.nlm.nih.gov/pubmed/35993913
http://dx.doi.org/10.1158/1078-0432.CCR-22-1493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713361/
https://www.ncbi.nlm.nih.gov/pubmed/35993913
http://dx.doi.org/10.1158/1078-0432.CCR-22-1493

Ejemplares similares